Sara Al Busaidi

Sara Al Busaidi

Auto-generated profile, based on publicly available information

Sara Al Busaidi

Medical Department, Sultan Qaboos University, Muscat, Sultanate of Oman

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
HLHanan Al Lawati
Hanan Al Lawati
SBSara Al Busaidi
Sara Al Busaidi
TRThuraiya Al Rawahi
Thuraiya Al Rawahi
ALAbdullah Al Lawati
Abdullah Al Lawati
AKAhmed Kifah
Ahmed Kifah
SDSrijit Das
Srijit Das
Osteoporosis is a major global health problem. The increase in the incidence of osteoporosis in the elderly poses a challenge to treat and also results in an economic burden for the nation. Osteoporosis has been given more importance in females, and there is an urgent need to address this disease in males. Various drugs, such as nitrogen-containing bisphosphonates, RANK ligand inhibitors, parathormones, and alendronate, have been used for effective treatment of osteoporosis. Alendronate (alendronic acid), a nitrogen-containing bisphosphonate that inhibits bone resorption by osteoclasts, was synthesized during the 1970s. In the present review, we discuss the pharmacokinetics, mechanism of action, adverse effects, contraindications, and toxicity monitoring of alendronate. The drug may be effectively used for the treatment of male osteoporosis in order to increase bone mineral density and prevent fractures.